Day: March 13, 2022

Children with three copies of SMN2 treated presymptomatically achieved age-appropriate milestones, including standing and walking; required no ventilatory or feeding tube support; and had no serious, treatment-related adverse eventsPost-hoc analyses of START, STR1VE-EU and STR1VE-US indicated children with SMA Type 1 achieved or maintained important measures of bulbar functionMore than 1,800 patients have now been treated with Zolgensma globally across clinical trials, managed access programs and in the commercial setting1Basel, March 13, 2022 — Novartis today announced new data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA). The completed Phase 3 SPR1NT study demonstrated that children with three copies of the SMN2 back-up...

ARLINGTON, Va., March 13, 2022 (GLOBE NEWSWIRE) — WTW, a leading global advisory, broking and solutions company, today announced it will withdraw from all of its businesses in Russia. Carl Hess, WTW’s CEO, said, “We continue to be dismayed by the crisis in Ukraine. WTW remains steadfast in our support for all our colleagues and their families in the region who have been affected. We wholeheartedly wish for a peaceful solution. WTW intends to transfer ownership of our Russian businesses to local management who will operate independently in the Russian market. While we strongly believe this is the right decision, it was not made in haste nor without consideration for our dedicated Russian colleagues.” About WTWAt WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging...

A single intravenous dose of NeuBase’s Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescues splicing, restores chloride channel (Clcn1) function, and durably reverses myotonia in the HSALR model Multiple subcutaneous doses also lead to molecular and functional rescue in the HSALR model demonstrating efficacy in a dose-dependent manner and potential feasibility of this patient-friendly administration route Company remains on track to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in 4Q CY2022 NeuBase management to host a conference call and webcast tomorrow, March 14, at 8:00 a.m. EDTPITTSBURGH and CAMBRIDGE, Mass., March 13, 2022 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”),...

–  For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value 600 mg/day of calcium supplements) with no increase in prescribed study drug within the 4 weeks prior to the Week 26 visit – was achieved by 78.7% of TransCon PTH-treated patients (48 of 61), compared to 4.8% for patients (1 of 21) in control group (p-value

Oslo, 13 March 2022: The CEO of Belships ASA (“the Company”), Lars Christian Skarsgård, has today exercised all his 5,000,000 options in the Company against cash settlement by the Company. The share options were granted to Skarsgård when he was appointed as the new CEO of the Company in 2019. The amount payable per share is equal to NOK 18,64 (equal to the VWAP of the share the last 10 business days prior to settlement) less the strike price of NOK 4.10. Furthermore, the board of directors of the Company has decided to grant Skarsgård 5,000,000 new options to subscribe for up to 5,000,000 shares in the Company with an exercise price of NOK 18.64 per share. The options can be exercised in the period between 36 months and 60 months from the date of grant. The company may honour exercised options by delivery of new shares in...

Root Inc., the parent company of Root Insurance, unveils car’s paint scheme for the first primary sponsored race with Bubba Wallace of the 2022 NASCAR Season COLUMBUS, Ohio, March 13, 2022 (GLOBE NEWSWIRE) — The No. 23 Root Insurance Toyota Camry makes its 2022 debut with 23XI Racing this Sunday, March 13, during the Ruoff Mortgage 500 NASCAR Cup Series race at Phoenix Raceway. Sunday’s race serves as the first of three races this season when the No. 23 Camry, driven by Bubba Wallace, will have Root Insurance as the primary sponsor. The car features a bold design based on a Hubble Space Telescope image from Wallace’s birthdate, October 8th. Root encouraged fans to find the Hubble view of their birthdays in links across their social media platforms. In response to the release of the car design, a tweet from the Hubble Space Telescope...

Successful Breakthrough of Biosynthetic Psilocybin Production Method Progressing Quickly VANCOUVER, British Columbia, March 12, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has set in motion steps to expand production of its proprietary biosynthesized psilocybin API (active pharmaceutical ingredient ), for utilization by pharmaceutical manufacturers involved in the development of psychedelic medicines, and delivered to compounding pharmacies for subsequent distribution to licensed physicians for use in authorized patient treatments. The proprietary production system for biosynthesized psilocybin that has been developed by Vocan scientists (Company press...